SCHEMBL1206930

SCHEMBL1206930

CS(=O)(=O)c1ccccc1-c1ccc(S(=O)(=O)O)cn1.NC(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 4/20 0.39
AVPR2 P30518 1/20 0.39
GPR27 Q9NS67 1/20 0.39
USP28 Q96RU2 2/20 0.39
ALB P02768 1/20 0.38
HTR1A P08908 1/20 0.38
SLC6A2 P23975 1/20 0.38
PDE4A P27815 1/20 0.38
OPRM1 P35372 1/20 0.38
DRD3 P35462 1/20 0.38
HTR2B P41595 1/20 0.38
SLC6A3 Q01959 1/20 0.38
PDE4D Q08499 1/20 0.38
SHH Q15465 1/20 0.38
SLC29A1 Q99808 1/20 0.38
SMO Q99835 1/20 0.38
ABCG2 Q9UNQ0 1/20 0.38
FLT1 P17948 3/20 0.38
FLT4 P35916 3/20 0.38
KDR P35968 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1206964 0.86 FLT1 (0.40) PDE4BGPR27USP28FLT1FLT4
SCHEMBL1206929 0.82 FLT1 (0.57) FLT1FLT4KDR
SCHEMBL1206402 0.81 FLT1 (0.46) PDE4BFLT1FLT4KDRKDM4E
SCHEMBL1207427 0.78 FLT1 (0.44) AVPR2GPR27FLT1FLT4KDR
SCHEMBL1206950 0.76 FLT1 (0.44) FLT1FLT4KDRCCR9ALDH1A1
SCHEMBL1206968 0.75 FLT1 (0.42) PDE4BFLT1FLT4KDRHTT
SCHEMBL1206947 0.75 KDM1A (0.42) AVPR2GPR27FLT1FLT4KDR
SCHEMBL4372151 0.74 BCL2L1 (0.46) PDE4BAVPR2GPR27OPRM1FLT1
SCHEMBL1206970 0.74 FLT1 (0.45) AVPR2GPR27FLT1FLT4KDR
SCHEMBL28026386 0.74 RAB9A (0.50) SMORAB9AKDM4EALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879884-B2 6-(2-Chloro-phenyl)-5-methyl-pyridine-3-sulfonic acid 2-chloro-4-fluoro-benzoylamide; potassium salt, used as antiproliferative, anticarcinogenic or antitumor agents HOFFMANN-LA ROCHE INC. (US) 2011-02-01 US claimed
US-20100256200-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-07 US claimed
EP-2148861-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. Hoffmann-Roche AG (CH) 2010-02-03 EP claimed
WO-2008138594-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2008-11-20 WO claimed
US-7879884-B2 6-(2-Chloro-phenyl)-5-methyl-pyridine-3-sulfonic acid 2-chloro-4-fluoro-benzoylamide; potassium salt, used as antiproliferative, anticarcinogenic or antitumor agents HOFFMANN-LA ROCHE INC. (US) 2011-02-01 US disclosed
US-20100256200-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-07 US disclosed
EP-2148861-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. Hoffmann-Roche AG (CH) 2010-02-03 EP disclosed
WO-2008138594-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256200-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS ARSA, STS, SULT2A1 PDE4B 1723/4885AVPR2 2880/4885GPR27 3127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.